Physician profile
Jarrett Hammer
NPI 1417152026
$7,264.30
in general payments reported to CMS, 2019-2025
46 companies · $976 in 2025
The $976 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $661 · 2021: $1,113 · 2022: $1,214 · 2023: $1,175 · 2024: $1,183 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,334.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,912.12 | 2020-2025 | |
| Pfizer INC. | $841.55 | 2019-2025 | |
| Novo Nordisk INC | $657.50 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $541.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $346.04 | 2019-2025 | Verquvo, Rotateq, Capvaxive |
| Sanofi-Aventis U.S. LLC | $314.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $293.53 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Allergan, INC. | $222.47 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $208.34 | 2022 | |
| Amgen INC. | $184.50 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $180.70 | 2019-2024 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.51 | 2019-2025 | Jardiance, Synjardy |
| Daiichi Sankyo INC. | $127.82 | 2020-2022 | |
| Astellas Pharma US INC | $125.83 | 2019-2025 | Veozah |
| Boston Scientific Corporation | $101.63 | 2024-2025 | Wavewriter Alpha Prime 16, Spaceoar Vue System - 10ml |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarrett Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.